These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31629575)

  • 1. Symptoms of Secondary Hyperparathyroidism in Patients Receiving Maintenance Hemodialysis: A Prospective Cohort Study.
    Levy AR; Xing S; Brunelli SM; Cooper K; Finkelstein FO; Germain MJ; Kimel M; Platt RW; Belozeroff V
    Am J Kidney Dis; 2020 Mar; 75(3):373-383. PubMed ID: 31629575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.
    Block GA; Bushinsky DA; Cheng S; Cunningham J; Dehmel B; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Moe SM; Patel UD; Silver J; Sun Y; Wang H; Chertow GM
    JAMA; 2017 Jan; 317(2):156-164. PubMed ID: 28097356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols.
    Chertow GM; Lu ZJ; Xu X; Knight TG; Goodman WG; Bushinsky DA; Block GA
    Hemodial Int; 2012 Apr; 16(2):188-97. PubMed ID: 22118402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 7-84 parathyroid hormone fragments are proportionally increased with the severity of uremic hyperparathyroidism.
    Chang JM; Lin SP; Kuo HT; Tsai JC; Tomino Y; Lai YH; Chen HC
    Clin Nephrol; 2005 May; 63(5):351-5. PubMed ID: 15909594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mental Effects of Excess Parathyroid Hormone in Hemodialysis Patients: A Possible Role for Parathyroid 2 Hormone Receptor?
    Diskin J; Diskin CJ
    Ther Apher Dial; 2020 Jun; 24(3):285-289. PubMed ID: 31423747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between the weight of parathyroid glands and their secretion of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Kakuta T; Tanaka R; Kanai G; Miyamoto Y; Inagaki M; Suzuki H; Fukagawa M; Saito A
    Ther Apher Dial; 2008 Oct; 12(5):385-90. PubMed ID: 18937722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism.
    Sanadgol H; Bayani M; Mohammadi M; Bayani B; Mashhadi MA
    Iran J Kidney Dis; 2011 Nov; 5(6):410-5. PubMed ID: 22057074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
    Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
    Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
    Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
    Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding.
    Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S
    Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.
    Rauscher S; Lafrance JP; Pichette V; Bell RZ; Desforges K; Lepage L; Ouellet G; Ouimet D; Leblanc M; Lamarche C; Bezzaoucha S; Vallee M
    Int Urol Nephrol; 2017 Feb; 49(2):325-328. PubMed ID: 27822674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials.
    Block GA; Bushinsky DA; Cunningham J; Drueke TB; Ketteler M; Kewalramani R; Martin KJ; Mix TC; Moe SM; Patel UD; Silver J; Spiegel DM; Sterling L; Walsh L; Chertow GM
    JAMA; 2017 Jan; 317(2):146-155. PubMed ID: 28097355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Early risk factors for secondary hyperparathyroidism in hemodialysis patients].
    Petrauskiene V; Bumblyte IA; Kuzminskis V; Sepetauskiene E
    Medicina (Kaunas); 2005; 41 Suppl 1():44-9. PubMed ID: 15901975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Secondary hyperparathyroidism: incidence, clinical presentations, treatment].
    Samokhvalova NA; Romanchishen AF; Gerasimchuk RP; Grinev KM; Zemchenkov AIu
    Vestn Khir Im I I Grek; 2007; 166(5):78-81. PubMed ID: 18154100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.
    Tentori F; Wang M; Bieber BA; Karaboyas A; Li Y; Jacobson SH; Andreucci VE; Fukagawa M; Frimat L; Mendelssohn DC; Port FK; Pisoni RL; Robinson BM
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):98-109. PubMed ID: 25516917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Lowering Dialysate Calcium Concentration on Mineral and Bone Disorders in Chronic Hemodialysis Patients: Conversion from 3.0 mEq/L to 2.75 mEq/L.
    Yamada S; Ueki K; Tokumoto M; Suehiro T; Kimura H; Taniguchi M; Fujimi S; Kitazono T; Tsuruya K
    Ther Apher Dial; 2016 Feb; 20(1):31-9. PubMed ID: 26482334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravenous alfacalcidol in the treatment of secondary hyperparathyroidism in patients on hemodialysis.
    González MT; Torregrosa JV; Colomé E; Mendia A; Pavesi M
    Nephron Clin Pract; 2008; 108(2):c141-7. PubMed ID: 18259100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism in patients on maintenance hemodialysis.
    Hida M
    Tokai J Exp Clin Med; 1982 Nov; 7(6):665-70. PubMed ID: 7184198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.